Revance Therapeutics Inc (RVNC)

[iwfal]

– Q4 DAXXIFY volume up 22% over Q3 2023, with over two-thirds of Q4 revenue attributable to reordering accounts.

Suggest that what they need is more new accounts. The problem is that it takes each account time to figure out how to use it outside Glabellar Lines, but once an account does… of course they switch over all the patients they can. More $. But the reorder percentage needs to drop (indicating new accounts willing to try).

Caveat: when the system is not yet stable it’s a lot harder to read this kind of number. It would be a LOT more reliable if they did new account orders vs existing account orders - instead of total volume.